Manjula Mahata, Ph.D.

Dr. Manjula Mahata is the Chief Scientific Officer (CSO) of CgA Therapeuticals Inc. She received her Ph.D. in comparative endocrinology at the University of Calcutta (India) in 1991. She then received advanced training and contributed towards Chromogranin A (CgA) regulation of health and diseases in reputed Institutions in Europe and the USA.

Dr. Mahata is the co-discoverer of the CgA-derived peptide Catestatin (CST: hCgA352-372) and has an in-depth knowledge on CST physiology. She has published over 100 peer-reviewed research articles in journals of international repute and authored several review articles/book chapters on CgA and CST.

As a CSO, she will seek more federal and private funding for CgA Therapeuticals Inc to advance clinical development of CST (21-mer), natural human variants of CST (G364S and P370L), retro-inverso CST (RI-CST, reversing sequence, as well as inverting chirality to all D-amino acids), D-CST (all D-amino acids), CST-R (22-mer), and TKO-10-18 (a small molecule CST-mimetic pharmacophore) as drugs to treat diabetes, obesity, hypertension, gastroparesis, leaky-gut, and sarcopenia.